Zhejiang Starry Pharmaceutical Co., Ltd.

The company was founded in 1997 and is a high-tech enterprise specializing in R&D, production and sales of X-CT nonionic contrast agent series and quinolone series of APIs and intermediates. The company takes “concentrating life energy and caring for human health” as its business philosophy, and “specialization to replace imports to fill domestic gaps” as its development policy, and continues to enrich the X-ray contrast agent series products. The company will strive to become a well-known pharmaceutical company in China and the world, and create an excellent “Stari” pharmaceutical brand. The company is a high-tech enterprise specializing in R&D, production and sales of pharmaceutical specialty APIs. The company's main products are nonionic iodine contrast agent series drugs. As a high-tech enterprise, the company undertook a number of national and provincial research projects, successfully completed the acceptance of the results, and obtained a number of certificates. The “non-ionic X-CT contrast agent raw material - iohexol” project undertaken by the company obtained the “National Torch Program Project Certificate” issued by the Torch High-tech Industrial Development Center of the Ministry of Science and Technology of the People's Republic of China. Iohexol was also rated as a “Zhejiang High-tech Product” by the Zhejiang Science and Technology Department and as a “Taizhou Famous Brand Product” by the Taizhou Famous Brand Product Accreditation Committee. The “Synthesis Process Development and Industrialization of High-purity Nonionic X-CT Contrast Agent - Iohexol” project was awarded the “Second Prize for Science and Technology of Zhejiang Province” and the “First Prize for Science and Technology Progress in Taizhou” by the Zhejiang Provincial People's Government and the Taizhou Municipal People's Government respectively.